Literature DB >> 16162271

Cholesterol depletion inhibits src family kinase-dependent calcium mobilization and apoptosis induced by rituximab crosslinking.

Tammy L Unruh1, Haidong Li, Cathlin M Mutch, Neda Shariat, Lana Grigoriou, Ratna Sanyal, Christopher B Brown, Julie P Deans.   

Abstract

The monoclonal antibody (mAb) rituximab produces objective clinical responses in patients with B-cell non-Hodgkin's lymphoma and antibody-based autoimmune diseases. Mechanisms mediating B-cell depletion by rituximab are not completely understood and may include direct effects of signalling via the target antigen CD20. Like most but not all CD20 mAbs, rituximab induces a sharp change in the solubility of the CD20 protein in the non-ionic detergent Triton-X-100, reflecting a dramatic increase in the innate affinity of CD20 for membrane raft signalling domains. Apoptosis induced by rituximab hypercrosslinking has been shown to require src family kinases (SFK), which are enriched in rafts. In this report we provide experimental evidence that SFK-dependent apoptotic signals induced by rituximab are raft dependent. Cholesterol depletion prevented the association of hypercrosslinked CD20 with detergent-insoluble rafts, and attenuated both calcium mobilization and apoptosis induced with rituximab. CD20 cocapped with the raft-associated transmembrane adaptor LAB/NTAL after hypercrosslinking with CD20 mAbs, regardless of their ability to induce a change in the affinity of CD20 for rafts. Taken together, the data demonstrate that CD20 hypercrosslinking via rituximab activates SFKs and downstream signalling events by clustering membrane rafts in which antibody-bound CD20 is localized in a high-affinity configuration.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16162271      PMCID: PMC1817827          DOI: 10.1111/j.1365-2567.2005.02213.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  43 in total

1.  Transient translocation of the B cell receptor and Src homology 2 domain-containing inositol phosphatase to lipid rafts: evidence toward a role in calcium regulation.

Authors:  R J Petrie; P P Schnetkamp; K D Patel; M Awasthi-Kalia; J P Deans
Journal:  J Immunol       Date:  2000-08-01       Impact factor: 5.422

2.  Rapid redistribution of CD20 to a low density detergent-insoluble membrane compartment.

Authors:  J P Deans; S M Robbins; M J Polyak; J A Savage
Journal:  J Biol Chem       Date:  1998-01-02       Impact factor: 5.157

Review 3.  Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma.

Authors:  D R Anderson; A Grillo-López; C Varns; K S Chambers; N Hanna
Journal:  Biochem Soc Trans       Date:  1997-05       Impact factor: 5.407

4.  Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.

Authors:  R A Clynes; T L Towers; L G Presta; J V Ravetch
Journal:  Nat Med       Date:  2000-04       Impact factor: 53.440

5.  Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies.

Authors:  D Shan; J A Ledbetter; O W Press
Journal:  Blood       Date:  1998-03-01       Impact factor: 22.113

6.  Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis.

Authors:  J Golay; L Zaffaroni; T Vaccari; M Lazzari; G M Borleri; S Bernasconi; F Tedesco; A Rambaldi; M Introna
Journal:  Blood       Date:  2000-06-15       Impact factor: 22.113

7.  SU6656, a selective src family kinase inhibitor, used to probe growth factor signaling.

Authors:  R A Blake; M A Broome; X Liu; J Wu; M Gishizky; L Sun; S A Courtneidge
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

8.  Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis.

Authors:  J K Hofmeister; D Cooney; K M Coggeshall
Journal:  Blood Cells Mol Dis       Date:  2000-04       Impact factor: 3.039

9.  In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas.

Authors:  Olivier Manches; Gabrielle Lui; Laurence Chaperot; Rémy Gressin; Jean-Paul Molens; Marie-Christine Jacob; Jean-Jacques Sotto; Dominique Leroux; Jean-Claude Bensa; Joël Plumas
Journal:  Blood       Date:  2002-10-03       Impact factor: 22.113

10.  Growth inhibition of CD20-positive B lymphoma cell lines by IDEC-C2B8 anti-CD20 monoclonal antibody.

Authors:  H Taji; Y Kagami; Y Okada; M Andou; Y Nishi; H Saito; M Seto; Y Morishima
Journal:  Jpn J Cancer Res       Date:  1998-07
View more
  20 in total

Review 1.  Role of lipid rafts in liver health and disease.

Authors:  Angela Dolganiuc
Journal:  World J Gastroenterol       Date:  2011-05-28       Impact factor: 5.742

2.  Clustering class I MHC modulates sensitivity of T cell recognition.

Authors:  David R Fooksman; Gigi Kwik Grönvall; Qing Tang; Michael Edidin
Journal:  J Immunol       Date:  2006-06-01       Impact factor: 5.422

3.  Induction of apoptosis by cross-linking antibodies bound to human B-lymphoma cells: expression of Annexin V binding sites on the antibody cap.

Authors:  M Jules Mattes; Rosana B Michel; David M Goldenberg; Robert M Sharkey
Journal:  Cancer Biother Radiopharm       Date:  2009-04       Impact factor: 3.099

4.  Drug-Free Macromolecular Therapeutics Induce Apoptosis via Calcium Influx and Mitochondrial Signaling Pathway.

Authors:  Lian Li; Jiyuan Yang; Jiawei Wang; Jindřich Kopeček
Journal:  Macromol Biosci       Date:  2017-08-14       Impact factor: 4.979

5.  Drug-free albumin-triggered sensitization of cancer cells to anticancer drugs.

Authors:  Lian Li; Jiyuan Yang; Sirima Soodvilai; Jiawei Wang; Praneet Opanasopit; Jindřich Kopeček
Journal:  J Control Release       Date:  2018-11-19       Impact factor: 9.776

6.  Amplification of CD20 Cross-Linking in Rituximab-Resistant B-Lymphoma Cells Enhances Apoptosis Induction by Drug-Free Macromolecular Therapeutics.

Authors:  Lian Li; Jiyuan Yang; Jiawei Wang; Jindřich Kopeček
Journal:  ACS Nano       Date:  2018-04-02       Impact factor: 15.881

Review 7.  Killing tumor cells through their surface beta(2)-microglobulin or major histocompatibility complex class I molecules.

Authors:  Jing Yang; Qing Yi
Journal:  Cancer       Date:  2010-04-01       Impact factor: 6.860

8.  Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma.

Authors:  Lapo Alinari; Bo Yu; Beth A Christian; Fengting Yan; Jungook Shin; Rosa Lapalombella; Erin Hertlein; Mark E Lustberg; Carl Quinion; Xiaoli Zhang; Gerard Lozanski; Natarajan Muthusamy; Mette Prætorius-Ibba; Owen A O'Connor; David M Goldenberg; John C Byrd; Kristie A Blum; Robert A Baiocchi
Journal:  Blood       Date:  2011-01-12       Impact factor: 22.113

9.  Tuning innate immune activation by surface texturing of polymer microparticles: the role of shape in inflammasome activation.

Authors:  Christine A Vaine; Milan K Patel; Jintao Zhu; Eunji Lee; Robert W Finberg; Ryan C Hayward; Evelyn A Kurt-Jones
Journal:  J Immunol       Date:  2013-02-20       Impact factor: 5.422

10.  Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells.

Authors:  Andrei Ivanov; Stephen A Beers; Claire A Walshe; Jamie Honeychurch; Waleed Alduaij; Kerry L Cox; Kathleen N Potter; Stephen Murray; Claude H T Chan; Tetyana Klymenko; Jekaterina Erenpreisa; Martin J Glennie; Tim M Illidge; Mark S Cragg
Journal:  J Clin Invest       Date:  2009-07-20       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.